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by a 1-week rest, five courses) or for 18 months (study 
group, 5 days of treatment followed by a 2-day rest, 15 
courses). treatment status and safety were evaluated.
Results a total of 1,071 patients were enrolled, and 
1,063 were included in safety analyses. treatment com-
pletion rate at 6 months was 74.0 % in the control group 
and 76.7 % in the study group. treatment completion rate 
in the study group at 18 months was 56.0 %. the overall 
incidence of adverse events (aes) was 75.3 % in the con-
trol group and 77.6 % in the study group. the incidences of 
grade 3 or higher aes were low in both groups. During the 
first 6 months, the incidences of the subjective aes were 
significantly lower in the study group.
Conclusions Oral UFt plus leucovorin given by either 
dosage schedule is a very safe regimen for adjuvant 
Abstract 
Purpose the JFMC33-0502 trial is a phase III clinical 
study designed to determine the most appropriate duration 
of postoperative adjuvant chemotherapy with uracil–tegafur 
(UFt) plus leucovorin in patients with stage IIB or III 
colon cancer. We report the interim results of preplanned 
safety analyses.
Methods Patients with stage IIB or III colon cancer who 
had undergone curative resection were randomly assigned 
to receive UFt (300 mg/m2) plus leucovorin (75 mg/day) 
for 6 months (control group, 4 weeks of treatment followed 
Electronic supplementary material the online version of this 
article (doi:10.1007/s00280-014-2461-5) contains supplementary 
material, which is available to authorized users.
t. tsuchiya (*) 




tokai University, Isehara, Japan
K. Sasaki 
Otaru ekisaikai Hospital, Otaru, Japan
K. Kondo 
national Hospital Organization nagoya Medical Hospital, 
nagoya, Japan
K. Katsumata 
tokyo Medical University, tokyo, Japan
g. nishimura 
Japanese red Cross Kanazawa Hospital, Kanazawa, Japan
Y. Kakeji 
Kobe University, Kobe, Japan
H. Baba 
Kumamoto University, Kumamoto, Japan
t. Morita 
aomori Prefectural Central Hospital, aomori, Japan
K. Koda 
teikyo University Chiba Medical Center, Ichihara, Japan
S. Sato 
School of Medicine, Fujita Health University, toyoake, Japan
J. Matsuoka 
Okayama University Hospital, Okayama, Japan
Y. Yamaguchi 
Kawasaki Medical School, Kurashiki, Japan
H. Usuki 
Kagawa University, Kagawa, Japan
C. Hamada 
tokyo University of Science, tokyo, Japan
1254 Cancer Chemother Pharmacol (2014) 73:1253–1261
1 3
chemotherapy. In particular, 5 days of treatment followed 
by a 2-day rest was a useful treatment option from the 
viewpoint of toxicity even when given for longer than 
6 months.
Keywords Colon cancer · adjuvant chemotherapy · 
Uracil–tegafur (UFt) · leucovorin · treatment duration
Introduction
adjuvant chemotherapy is standard treatment for stage 
III colon cancer and has also been recommended for the 
management of high-risk stage II colon cancer [1]. Several 
studies have examined the optimal duration of postopera-
tive adjuvant chemotherapy, but clear conclusions were not 
obtained [2–4].
In recent studies of adjuvant chemotherapy for colon 
cancer performed in Western countries, the duration of 
treatment was 6 months for regimens, such as 5-fluoroura-
cil plus leucovorin, oral uracil–tegafur (UFt) plus leucov-
orin, oral capecitabine, and FOlFOX (oxaliplatin, 5-fluo-
rouracil, and leucovorin) [5–7]. therefore, 6 months of 
adjuvant chemotherapy has been standard, even in routine 
clinical practice.
an analysis of the adjuvant Colon Cancer endpoints 
(aCCent) database showed that recurrence of colorectal 
cancer reaches a peak between 1 and 2 years after surgery 
[8]. Sadahiro et al. [9] reported that the cumulative recur-
rence rate of colon cancer in their series was 43 % at 1 year 
and 77 % at 2 years. this finding suggests that adjuvant 
chemotherapy for longer than 6 months may more signifi-
cantly reduce recurrence and improve survival rates. In clini-
cal trials performed in Japan, 1 year or 2 years of postop-
erative adjuvant chemotherapy with UFt alone significantly 
improved survival rates as compared with surgery alone in 
patients with rectal or colorectal cancer [10, 11]. In patients 
with stage I lung adenocarcinoma, 2 years of UFt mono-
therapy revealed significant impact on survival [12]. the 
optimal duration of adjuvant chemotherapy may thus differ 
according to the type of cancer and treatment regimen.
We conducted a large phase III clinical trial comparing 
6 months with 18 months of oral UFt plus leucovorin to 
determine the optimal duration of postoperative adjuvant 
chemotherapy for patients with high-risk stage II and stage 
III colon cancer.
We report the interim results of a preplanned safety anal-
ysis of adverse events (aes) and an analysis of completion 
rates.
Materials and methods
this study was conducted in accordance with the Declara-
tion of Helsinki and ethical guidelines for clinical research 
(overall revision dated December 28, 2004) and was 
approved by the institutional review boards of each par-
ticipating hospital. Written informed consent was obtained 
from all patients who participated in the study.
the main eligibility criteria were as follows: (1) a his-
tologically confirmed colorectal cancer; (2) a pathologi-
cal classification of stage IIB (t4, n0, M0), IIIa (t1–2, 
n1, M0), IIIB (t3–4, n1, M0), or IIIC (any t, n2, M0) 
cancer of the colon (cecum, ascending colon, transverse 
colon, descending colon, sigmoid colon) or rectum (only 
the rectosigmoid) according to the sixth edition of tumor-
node-metastasis classification of the International Union 
against Cancer; (3) radical resection of colorectal cancer 
with extended (D2 or more) lymph node dissection; (4) 
histologic curative resection; (5) aged 20–75 years; (6) an 
eastern Cooperative Oncology group performance status 
(PS) of 0 or 1; (7) no previous chemotherapy or radiother-
apy; (8) ability to orally ingest a normal diet and to receive 
oral drugs; (9) adequate organ function; (10) ability to start 
postoperative adjuvant chemotherapy within 6 weeks after 
surgery.
Patients who were confirmed to be eligible and enrolled 
were randomly assigned to receive UFt plus leucovorin 
for 6 months (control group, standard treatment) or for 
18 months (study group, study treatment). the treatment 
assignments were randomized at the registration office. 
a minimization method was used to balance assignments 
according to the following stratifying factors: tnM t cat-
egory (t1–2, t3, t4), n category (n0, n1, n2), surgical 
procedure (laparoscopic surgery, open surgery), and hospi-
tal. the study investigators and patients were not blinded to 
the treatment assignments.
the control group received UFt (300 mg/m2/day as 
tegafur) orally in three divided doses per day (every about 
8 h), avoiding 1 h before and after meals. leucovorin 
(75 mg/day) was given orally in three divided doses per 
day at the same times as UFt. Drugs were administered 
for 28 consecutive days, followed by a 7-day rest (consec-
utive-day treatment), and this was defined as one course 
of treatment. Five courses of treatment (6 months) were 
administered. the study group received UFt plus leucov-
orin at the same dose level as the control group. the drugs 
were administered orally for five consecutive days, fol-
lowed by a 2-day rest. Five weeks of this regimen (5 days 
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of treatment followed by a 2-day rest on Saturday and 
Sunday) were defined as one course of treatment, and 15 
courses (18 months) were administered (Fig. 1).
after completing the scheduled number of treatment 
courses in each group, patients were followed up with 
no further treatment until confirmation of metastasis or 
recurrence.
the assigned treatment was started within 6 weeks 
after surgery. During protocol treatment, clinical findings 
and laboratory data were evaluated every 2 weeks during 
the first two courses of treatment and then on the day of 
starting each subsequent course. the following condi-
tions had to be met at the start of each course: white cell 
count ≥3 × 103/µl and <12 × 103/µl, neutrophil count 
≥1,500/µl, hemoglobin level ≥9.0 g/dl, platelet count 
≥100 × 103/µl, serum total bilirubin level <1.5 mg/dl, 
serum aspartate aminotransferase and alanine aminotrans-
ferase levels <100 IU/l, serum creatinine level <1.5 mg/dl, 
no diarrhea (watery stools), and ≤grade 1 nonhematologic 
toxicity (with the exception of constipation, alopecia). If 
the criteria for starting/continuing treatment were not met, 
treatment was postponed or suspended until aes resolved, 
and the criteria for treatment resumption were met. If the 
treatment was suspended because of grade 3 or higher aes, 
only the dose of UFt was reduced by one level when the 
treatment was resumed. after resuming treatment at one 
lower dose level, the dose of UFt was not increased again, 
even if the toxicity resolved.
the criteria for discontinuing protocol treatment were as 
follows: the presence of progressive disease (metastasis or 
recurrence); serious aes and complications that preclude 
the continuation of treatment; a request by the patient; 
inability to resume treatment within 21 days after treat-
ment suspension; the same toxicity occurs after reducing 
the dose of UFt by two levels; and the study investigator 




treatment status, such as the daily dose, number of dosing, 
treatment suspension, dose reduction, and treatment discon-
tinuation, was collected from the case report forms of each 
patient. the treatment completion rate was defined as the 
percentage of patients who completed five courses of treat-
ment in the control group and the percentage of patients 
who completed 15 courses of treatment in the study group.
Safety profile
adverse events were evaluated according to the Common 
terminology Criteria for adverse events (CtCae), Japa-
nese translation, version 3.0, prepared by the Japan Clini-
cal Oncology group (JCOg) and Japan Society of Clini-
cal Oncology (JSCO). the most severe grade of aes up 
to 30 days after the completion of treatment was recorded. 
the following categories of aes were listed in the case 
report forms, and evaluation of the grade was required: 
hemoglobin level, white cell count, neutrophil count, 
platelet count, serum aspartate aminotransferase and ala-
nine aminotransferase levels, serum alkaline phosphatase 
level, serum total bilirubin level, serum blood urea nitro-
gen level, serum creatinine level, anorexia, nausea, vomit-
ing, stomatitis, diarrhea, rash or desquamation, hand-foot 
skin reactions, alopecia, easily fatigued (asthenia, malaise, 
and narcolepsy), and arrhythmias. Statistical analysis was 
performed with the use of SaS software, release 9.2 (SaS 
Institute, Cary, nC, USa). the Pearson chi-square test was 
conducted to compare the rate of aes between arms at two-
tailed 0.05 significant level.
Results
Patient characteristics
From October 2005 through September 2007, a total of 
1,071 patients were enrolled from 233 hospitals in Japan. 
after excluding 8 patients because of the reasons shown in 
Fig. 2, 1,063 patients were included in the safety analysis 
(control group, 531 patients; study group, 532 patients). all 
data were finalized on February 2013. table 1 shows the 
demographics of the 1,063 patients.
treatment status
the completion rate of protocol treatment at 6 months was 
similar in the control group (74.0 %) and in the study group 
Fig. 1  Dose schedule
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(76.7 %). the final treatment completion rate in the study 
group was 56.0 % (table 2).
Dose reduction was required in 15.3 % of patients in the 
control group as compared with 9.8 % in the study group at 
6 months. treatment suspension was observed at 36.0 % of 
patients in the control group and 33.6 % in the study group 
(table 3). as for the reasons for discontinuing treatment, 
the proportion of patients who stopped to continue treat-
ment for reasons other than aes was higher in the study 
group than in the control group (table 4). In patients who 
discontinued treatment because of aes, the number of 
patients who discontinued the treatment during the first 
course of treatment was higher in the control group (31 
patients) than in the study group (12 patients) (Fig. 3).
Safety profile
at the completion of 5 courses of treatment, aes at any 
grade had been reported in 75.3 % of patients in the control 
group and 69.2 % of those in the study group. the rates of 
grade 3 or higher aes were 16.2 % in the control group and 
10.0 % in the study group. table 5 shows aes at the com-
pletion of 5 courses of treatment. the incidences of aes 
in hemoglobin levels, blood urea nitrogen levels, anorexia, 
nausea, vomiting, stomatitis, diarrhea, and fatigue (any 
grade) were significantly lower in the study group than in 
the control group. the rate of grade 3 or higher diarrhea 
was 7.2 % in the control group and 2.4 % in the study 
group. During treatment courses 6–10 (6–12 months) and 
11–15 (12–18 months) in the study group, the incidences of 
grade 3 or higher aes were 1 % or less (table 6). Moreo-
ver, the incidences of nonhematologic toxicity, including 
anorexia, nausea, diarrhea, and fatigue, tended to be low. 
the overall incidence of aes during 15 courses of treat-
ment in the study group was 77.6 %; the incidence of grade 
3 or higher aes was 14.1 %. there was no treatment-
related death in either group.
Discussion
the nSaBP C06 study showed that oral UFt plus leucov-
orin is noninferior to intravenous 5-fluorouracil plus leuco-
vorin in patients with stage II or III colon cancer [5]. the 
JCOg0205 study confirmed the noninferiority of oral UFt 
plus leucovorin to intravenous fluorouracil and leucovorin 
in Japanese patients with stage III colon cancer [13]. these 
results established oral UFt plus leucovorin as one of a 
standard regimen for postoperative adjuvant chemotherapy 
in patients with colon cancer [14]. the standard duration 
of adjuvant chemotherapy has been 6 months in Western 
countries. However, a retrospective study of patients with 
stage III colon cancer who were 65 years or older reported 
that patients who received 5-fluorouracil-based chemother-
apy for 5–7 months had better overall survival than those 
who received similar therapy for 1–4 months [15].
Present study was conducted to evaluate the effective-
ness of prolongation of treatment duration in adjuvant 
chemotherapy with oral UFt plus leucovorin. the control 
group received oral UFt plus leucovorin for four consecu-
tive weeks followed by a 1-week rest, a conventionally 
used regimen, for 6 months. In the study group, oral UFt 
plus leucovorin was given for 5 days followed by a 2-day 
rest and a treatment schedule associated with mild toxicity 
and good compliance, for a total of 18 months.
the incidence of aes was lower in the study group 
(69.2 %) than in the control group (75.3 %) at 6 months. 
even at the completion of 18-month treatment in the 
study group, the incidence of aes (77.6 %) was similar to 
that at 6 months in the control group. In the study group, 
Fig. 2  allocation of patients
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Table 1  Patient characteristics Control group Study group total
n = 534 % n = 537 % n = 1,071 %
gender
 Male 294 55.1 264 49.2 558 52.1
 Female 240 44.9 273 50.8 513 47.9
age
 ≤50 51 9.6 51 9.5 102 9.5
 51–60 140 26.2 154 28.7 294 27.5
 61–70 231 43.3 228 42.5 459 42.9
 71–80 112 21.0 104 19.4 216 20.2
 Median 64 [23–75] 64 [24–75] 64 [23–75]
PS
 0 503 94.2 517 96.3 1,020 95.2
 1 31 5.8 20 3.7 51 4.8
tumor location
 right colon (C, a, t) 199 37.3 218 40.6 417 39.0
 left colon (D, S) 221 41.4 211 39.3 432 40.3
 rs 114 21.3 108 20.1 222 20.7
Operative procedure
 laparoscopic 109 20.4 110 20.5 219 20.4
 laparotomy 425 79.6 427 79.5 852 79.6
Histologic types
 Wel 187 35.0 190 35.4 377 35.2
 Mod 308 57.7 307 57.2 615 57.4
 Por 19 3.6 20 3.7 39 3.6
 Muc 20 3.7 18 3.4 38 3.5
 Sig 0 0.0 2 0.4 2 0.2
t (tnM 6th)
 t1 16 3.0 16 3.0 32 3.0
 t2 51 9.6 45 8.4 96 9.0
 t3 283 53.0 272 50.7 555 51.8
 t4 184 34.5 204 38.0 388 36.2
n (tnM 6th)
 n0 69 12.9 75 14.0 144 13.4
 n1 347 65.0 352 65.5 699 65.3
 n2 118 22.1 110 20.5 228 21.3
Stage (tnM 6th)
 I 1 0.2 0 0.0 1 0.1
 IIa 2 0.4 1 0.2 3 0.3
 IIB 66 12.4 74 13.8 140 13.1
 IIIa 59 11.0 57 10.6 116 10.8
 IIIB 288 53.9 295 54.9 583 54.4
 IIIC 118 22.1 110 20.5 228 21.3
extent of ln dissection
 D2 147 27.5 136 25.3 283 26.4
 D3 387 72.5 391 72.8 778 72.6
no. of ln examined
 <12 165 30.9 151 28.1 316 29.5
 ≥12 369 69.1 386 71.9 755 70.5
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the incidences of nonhematologic toxic effects, such as 
anorexia, diarrhea, and fatigue (i.e., symptoms likely to 
affect treatment compliance), were significantly lower 
than that associated with the conventional treatment 
schedule in the control group. these findings suggested 
that treatment for 5 days followed by 2 days of rest con-
tributed to lower incidences of aes during 18 months of 
anticancer therapy.
at 6 months, the rate of discontinuing treatment 
because of aes was 21.7 % in the control group as com-
pared with only 8.9 % in the study group. this finding is 
considered to reflect the milder aes associated with the 
treatment schedule in the study group. the most com-
mon grade 3 or higher ae was diarrhea (7.2 %) in the 
control group. the incidences of all other grade or higher 
aes were less than 5 % in both groups. these results 
showed that both treatment schedules were acceptable 
as regimens for postoperative adjuvant chemotherapy; 
however, 5 days of treatment followed by 2 day of rest 
can be more strongly recommended for long-term treat-
ment because of the lower incidences of aes. the rate 
of completing 18 months of treatment in the study group 
was only 56.0 % although the incidence of aes was low. 
One possible reason might be the financial burden asso-
ciated with the prolonged duration of treatment. Patients 
participating in the Japanese national health insurance 
system generally have to directly pay 30 % of total 
medical fees. Consequently, patients would have to pay 
about 10,000 U.S. dollars (1 million yen) to complete 
18 months of treatment in the study group. In fact, the 
proportion of patients who requested to discontinue treat-
ment for reasons other than aes was higher in the study 
group (18 %, 43/233) than in the control group (10.1 %, 
14/139), suggesting the involvement of economic fac-
tors. to our knowledge, no previous study has reported 
on the completion rate of 6 months or more of adjuvant 
chemotherapy with UFt and leucovorin in patients with 
colorectal cancer. One study evaluating 2 years of treat-
ment with UFt alone without leucovorin in patients 
who underwent radical resection of Dukes B or C colon 
cancer, performed by the tokai adjuvant Chemotherapy 
Study group for Colorectal (taC–Cr), reported that 
69.7 % of patients completed 1 year or more of treat-
ment [11]. In another study assessing 1 year of treat-
ment with UFt alone in patients who underwent radical 
resection of stage III colorectal cancer, conducted by the 
national Surgical adjuvant Study of Colorectal Cancer 
Table 2  rates of treatment completion




n = 531 % n = 532 %
Discontinuation in 1–5 courses 138 26.0 124 23.3
6–10 courses 70 13.2
11–15 courses 35 6.6
Unknown 0 0.0 1 0.2
treatment completion in 1–5 
courses (6 months)
393 74.0 298 56.0
393 74.0 408 76.7
Table 3  Percentages of patients who required dose reduction and 
those who discontinued treatment during 1–5 courses of treatment 
(6 months)
Control group 
(n = 531) (%)
Study group 
(n = 532) (%)
total 
(n = 1,052) (%)
Dose reduction
 (−) 84.7 90.2 87.5
 (+) 15.3 9.8 12.5
treatment discontinuation
 (−) 64.0 66.4 65.2
 (+) 36.0 33.6 34.8
Table 4  reasons for discontinuation during 1–5 courses of treatment 
(6 months)
reason for discontinuation Control group Study group
n = 138 % n = 124 %
Severe aes
 Hematologic toxicity 2 1.4 6 4.8
 nonhematologic toxicity 30 21.7 20 16.1
 Complication 5 3.6 4 3.2
Patient refusal
 reasons other than aes 14 10.1 23 18.5
 Because of aes 30 21.7 11 8.9
Over rest period 32 23.2 37 29.8
Others 25 18.1 23 18.5
Fig. 3  adverse events responsible for discontinuation during 1–5 
courses of treatment
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(nSaS-CC), the completion rate of 1 year of treatment 
was 80.3 % [10]. the treatment completion rates in both 
of these studies were higher than that in the study group 
of the present study (56.3 %). the toxicity associated 
with UFt plus leucovorin is stronger than that associated 
with UFt alone, and it may affect the completion rates 
of long-term adjuvant chemotherapy. Our results sug-
gest that the use of modified treatment regimens, such as 
5 days of treatment followed by 2 days of rest, is needed 
to maintain long-term drug compliance in UFt and leu-
covorin chemotherapy.
the incidence of grade 3 or higher diarrhea in our 
study was 7.2 % in the control group and 2.4 % in the 
study group. In a recent phase III study [adjuvant chemo-
therapy trial of tS-1 for colon cancer (aCtS-CC) trial] 
comparing 6 months of UFt plus leucovorin with S-1 as 
adjuvant chemotherapy in patients with stage III colon 
cancer, the incidence of grade 3 or higher diarrhea was 
5.5 % in the UFt plus leucovorin group [16], similar to 
our results. In the nSaBP C06 trial, performed in West-
ern countries, the incidence of grade 3 or higher diarrhea 
was as much as 29.4 % in the UFt plus leucovorin group 
[5]. the difference in the incidence of severe diarrhea 
between Western countries and Japan might be attributed 
to racial differences. In the present study, the incidence 
of diarrhea in any grade at 6 months was lower in the 
Table 5  aes during 1–5 
courses of treatment (6 months) 
in each group
* Pearson’s chi-square test
Control group (n = 531) Study group (n = 532) any grade, 
p value*
any grade (%) ≥grade 3 (%) any grade (%) ≥grade 3 (%)
Hb 31.6 0.0 26.1 0.4 0.050
WBC 13.2 0.0 13.3 0.4 1.000
neut 8.7 0.4 9.2 1.5 0.830
Plt 5.3 0.0 6.8 0.0 0.367
aSt 23.5 3.4 20.5 1.9 0.237
alt 24.9 4.7 22.2 1.9 0.312
al-p 11.9 0.8 12.4 0.4 0.851
t-Bil 25.4 1.9 24.2 0.8 0.671
BUn 6.0 0.2 3.4 0.0 0.044
Creatinine 6.6 0.0 5.1 0.0 0.299
anorexia 26.4 3.8 18.6 1.5 <0.01
nausea 20.5 1.1 11.5 0.8 <0.01
Vomiting 8.5 0.2 3.6 0.4 <0.01
Stomatitis 13.4 1.1 8.6 0.0 0.014
Diarrhea 28.1 7.2 14.8 2.4 <0.01
rash 6.8 0.2 5.6 0.4 0.449
Hand-foot 8.5 0.8 7.7 0.2 0.655
alopecia 1.9 0.0 1.9 0.0 1.000
Fatigue 21.8 2.6 16.7 1.3 0.036
Table 6  aes during 6–10 courses of treatment and during 11–15 
courses of treatment in the study group
Study group (n = 403)  
in 6–10 courses
Study group (n = 333)  
in 11–15 courses
any grade  
(%)
≥grade 3  
(%)




Hb 20.8 0.7 17.7 0.0
WBC 13.4 0.0 12.9 0.6
neut 7.9 0.7 6.0 0.6
Plt 10.2 0.0 10.5 0.3
aSt 18.6 0.0 14.7 0.6
alt 18.6 0.2 12.9 0.6
al-p 12.7 0.0 13.2 0.3
t-Bil 27.0 0.5 28.8 0.0
BUn 3.2 0.0 4.8 0.0
Creatinine 2.7 0.0 3.6 0.0
anorexia 8.7 0.5 4.8 0.0
nausea 4.7 0.0 3.0 0.0
Vomiting 3.2 0.0 0.9 0.0
Stomatitis 7.7 0.0 5.4 0.0
Diarrhea 9.7 0.2 6.6 0.0
rash 5.0 0.0 3.6 0.0
Hand-foot 9.9 1.0 7.8 0.3
alopecia 0.7 0.0 0.0 0.0
Fatigue 9.7 0.5 6.6 0.0
1260 Cancer Chemother Pharmacol (2014) 73:1253–1261
1 3
study group (15.0 %) than in the control group (28.3 %). 
therefore, the treatment schedule which consists of 5 
days of UFt plus lV and 2 days of treatment rest may 
be a more feasible treatment option for use in Western 
countries.
In conclusion, oral UFt plus leucovorin was associ-
ated with a low incidence of aes, indicating that it is a 
safe regimen as adjuvant chemotherapy. In particular, our 
results showed that the treatment schedule which consists 
of 5 days of UFt plus lV and 2 days of treatment rest was 
associated with a lower incidence of aes when treatment 
continues more than 6 months or longer period. Because 
5 days of treatment followed by 2 days of rest is not asso-
ciated with a lower dose intensity than the standard regi-
men for UFt plus leucovorin, it is a useful treatment option 
from the viewpoint of toxicity.
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